We demonstrated that SPRY4 undergoes a dynamic palmitoylation cycle regulated by ZDHHC7 and PPT1, which modulates MAPK signaling and subsequently affects tumor cell proliferation, migration, apoptosis, and drug resistance. This evidence concerns the gene SPRY4 and neoplasm.